Angiomyolipomas and Recurrent Bleeding Risk

Risk Factors for Recurrent Bleeding

Angiomyolipomas (AMLs) can cause bleeding on more than one occasion, with bleeding complications occurring mostly between ages 15-50 years, although the risk is present at any age, according to Nature Reviews Nephrology 1, 2
AMLs have a significant risk of spontaneous hemorrhage that can range from limited perirenal hematoma to life-threatening internal hemorrhage, as reported in Nature Reviews Nephrology 2
The lifetime risk of spontaneous hemorrhage from AMLs may exceed 20%, particularly for larger lesions, as found in Clinical Cancer Research 3
Larger tumor size (>3 cm in diameter) is associated with an increased risk of subsequent bleeding events, as noted in Nature Reviews Nephrology 1, 4
Association with tuberous sclerosis complex (TSC) increases the risk of bleeding, according to Nature Reviews Nephrology 1, 2

The natural history of AMLs includes the potential for multiple bleeding episodes over time, as described in Nature Reviews Nephrology 1
The risk of bleeding is continuous and present throughout the patient's lifetime, requiring ongoing monitoring, as stated in Nature Reviews Nephrology 1, 2

Strict kidney imaging follow-up is needed to monitor the risk of bleeding due to AML rupture, as recommended in Nature Reviews Nephrology 1, 2
Age correlates strongly with the frequency, number, and size of kidney lesions in patients with TSC, as reported in Nature Reviews Nephrology 1
The growth rate of AMLs is typically slow before adolescence, accelerates during adolescence and young adulthood, and then slows after age 40, as described in Nature Reviews Nephrology 1, 2
Pregnancy is associated with an increased risk of bleeding from AMLs, as found in the European Respiratory Journal 5

mTORC1 inhibition therapy can be used for AMLs presenting substantial bleeding risk, as noted in Nature Reviews Nephrology 1, 4

Patients should be warned about the risk of recurrent bleeding and instructed to seek urgent medical attention if symptoms of bleeding occur, as advised in the European Respiratory Journal 6
Pregnant women with AMLs should receive information about the increased risk of bleeding during pregnancy, as recommended in the European Respiratory Journal 5